Large data-driven analyses have identified distinct clinical sepsis phenotypes with differing trajectories and treatment responsiveness [15], suggesting that therapies such as PMX-HP are likely to have heterogeneous effects depending on when and in whom they are applied. This evidence concerns the gene HP and Sepsis.